Is CymaBay Therapeutics, Inc. (CBAY) a Buy, Sell, or Hold?
NASDAQ : CBAY
CymaBay Therapeutics, Inc. — Stock Grades
$32.48 USD
$0.01 (0.03%)
- Volume
- 8.35M
- Average Volume
- 4.16M
- Market Capitalization
- $3.73B
- P/E Ratio
- -32.81
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $32.50
- Year Low
- $7.26
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.96
CBAY Stock Grades
| Date | Grading Company | Previous Grade | New Grade | Action |
|---|---|---|---|---|
| 2024-02-29 | HC Wainwright & Co. | Neutral | Neutral | Maintain |
| 2024-02-20 | Leerink Partners | Outperform | Market Perform | Downgrade |
| 2024-02-14 | Piper Sandler | Overweight | Neutral | Downgrade |
| 2024-02-14 | UBS | Buy | Neutral | Downgrade |
| 2024-02-14 | LifeSci Capital | Outperform | Market Perform | Downgrade |
| 2024-02-13 | B. Riley Securities | Buy | Neutral | Downgrade |
| 2024-02-13 | Raymond James | Strong Buy | Market Perform | Downgrade |
| 2024-02-13 | JonesTrading | Buy | Hold | Downgrade |
| 2024-02-13 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| 2024-02-13 | BTIG | Buy | Neutral | Downgrade |
| 2024-02-13 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
| 2024-02-12 | William Blair | Outperform | Market Perform | Downgrade |